Unique structure of ozoralizumab, a trivalent anti-TNFα NANOBODY^® compound, offers the potential advantage of mitigating the risk of immune complex-induced inflammation.

ABSTRACT: Biologics have become an important component of treatment strategies for a variety of diseases, but the immunogenicity of large immune complexes (ICs) and aggregates of biologics may increase risk of adverse events is a concern for biologics and it remains unclear whether large ICs consisting of intrinsic antigen and therapeutic antibodies are actually involved in acute local inflammation such as injection site reaction (ISR). Ozoralizumab is a trivalent, bispecific NANOBODY^® compound that differs structurally from IgGs. Treatment with ozoralizumab has been shown to provide beneficial effects in the treatment of rheumatoid arthritis (RA) comparable to those obtained with other TNFα inhibitors. Very few ISRs (2%) have been reported after ozoralizumab administration, and the drug

SUBMITTER: Kyuuma M 

PROVIDER: S-EPMC10141648 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature